February 18, 2025--(BUSINESS WIRE)--GeneDx Holdings Corp. (Nasdaq ... collaborated with researchers from Wellcome Sanger Institute to release data from the largest and most diverse study to ...

GeneDx Holdings Corp. (Nasdaq: WGS) today reported its financial results for the fourth quarter and full year of 2024.

VolitionRx Limited ("Volition"), a multi-national epigenetics company, today announced the expansion of its Nu.Q® Vet Cancer Test supply agreement (the "Agreement") with Fujifilm Vet Systems Co. Ltd ( ...

MIAMI, Feb. 27, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the ...

OPKO Health, Inc. (NASDAQ: OPK) reports business highlights and financial results for the three and 12 months ended December 31, 2024. Highlights from the fourth ...

Operator Good day, and welcome to the OPKO Health fourth quarter 2024 financial results conference call. All participants will be in a listen-only mode. [Operator instructions] After today's ...

GAITHERSBURG, Md., March 13, 2025--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), a leader in delivering improved health outcomes through genomic insights, announced today its scientific contributions ...

GeneDx Holdings Corp. (NASDAQ:WGS) is a growth business. Having delivered a strong end to 2024, its outlook for 2025 points to another year of robust growth ahead. However, the business isn't ...

Principal Financial Group Inc. raised its stake in shares of GeneDx Holdings Corp. (NASDAQ:WGS – Free Report) by 10.6% in the ...